## This requisition is to be used by SCH/SCCA providers only.

For all <u>non-SCH/SCCA</u> providers, please use the "Bone Marrow" requisition located in the "Requisitions" section of the Online Test Catalog.

Ordering Physician:	Pager:				
	!				
COLLECTION DATE	COLLECTION TIME				
COLLECTION DATE: REQUIRED	COLLECTION TIME: REQUIRED				
☐ Special Priority, need results by:	REQUIRED				
Date and time:		AD		DATIENT I ADEI	
		I.	DRESSOGRAPH /	PATIENT LABEL	
SEATTLE CANCER CARE ALLIANCE	Multiple Lab Requisition Seattle Children's Modernal - RESEARCH - FOUNDATION				
Physicians should only order tests that are medically necessary for diagnosis or treatment of the patient.	PLEASE FILL OUT A SEPARATE ORDER FORM FOR EACH SPECIMEN TYPE:				
Appropriate diagnosis or ICD-9 coding MUST be provided. You should be aware that Medicare generally does not cover routine screening tests.	PLEASE SUBMIT A SEPARATE SAMPLE FOR EACH LAB  □Peripheral Blood: Infants: 1-2 mL; Children: 3-5 mL; Adults: 10-20 mL				
DIAGNOSIS:	□Bone Marrow: 1-2 mL each lab				
☐ Acute Myeloid Leukemia	Other:				
☐ Acute Lymphocytic Leukemia		Bilateral bone marrow aspirates will be pooled in testing lab for all testing except morphology			
□ B-cell □ T-cell	unless otherwise indicated	and be been an east.	g 101 w	a testing energy morphology	
☐ Chronic Myelogenous Leukemia	To SCCA Pathology: 825 Eastlake Ave 288-1355				
☐ Chronic Lymphocytic Leukemia	MORPHOLOGY				
☐ MDS ☐ primary ☐ secondary	☐Bone Marrow Aspirate	<b>□Other Tissue</b>			
☐ Myeloma	□Unilateral	Specin	nen Type	Site	
☐ Non-Hodgkin's Lymphoma	(Site):				
□ B-cell □ T-cell	□Bilateral	A			
☐ Hodgkin's Lymphoma					
☐ Aplastic Anemia	☐Bone Marrow Biopsy	В			
□ PNH	□Unilateral				
☐ Cytogenetics or molecular abnormality:	(Site): □Bilateral	. C			
Other:		D			
		b ——			
INDICATIONS:		${f E}$			
(CHECK ALL THAT APPLY)	PROVIDER: for all patients with mysles		'MI anlastic an	amia nauroblastoma and other solid	
☐ Pre transplant work-up	<b>PROVIDER:</b> for all patients with myelodysplasia, myelofibrosis, CML, aplastic anemia, neuroblastoma and other solid tumors, order a bone marrow biopsy in addition to aspirate in CIS. Patients with neuroblastoma and lymphoma should have				
☐ Monitoring post transplant; DAY#	bilateral biopsies; unilateral sampling is suffice	•		, in the second	
☐ Suspected relapse of original disease					
☐ Suspected graft failure/rejection	To SCCA Labs:	Green Top/ Heparin	825 Easlake Av	ve Cyto: 288-1395; Chimerisms: 288-1139	
☐ Suspected PTLD	☐ Chromosome analysis				
☐ Suspected GVHD	☐ FISH - Specify probe(s):			_	
☐ Suspected Secondary Malignancy	☐ Chimerism without cell sorting				
☐ Pre 2 <sup>nd</sup> Transplant (Allo or Auto)					
☐ Post 2 <sup>nd</sup> Transplant; DAY#	To UW Hematopathology:		Green Top/	<b>Heparin</b> 825 Eastlake Ave 288-7060	
☐ Consult	FLOW CYTOMETRY/CELL SORTING				
□ Donor	☐ Immunophenotyping				
☐ Confirm Identical Twin	☐ Immunophenotyping for suspected PTLD (STAT)				
□ Other:	☐ Cell sorting for chimerism – Cells to be sorted: Cell Sorting not typically done on Bone Marrow				
	□ CD3 □ CD33 □ CD56(N	IK) □ blasts			
TRANSPLANT TYPE:	☐ Other:				
☐ Myeloablative Allo					
Reduced Intensity Allo	To UW Molecular Hematopatholo	gy:	Purple To	<b>op/EDTA</b> 825 Eastlake Ave 288-7070	
□ Non-myeloablative Allo	MOLECULAR PCR STUDIES	~~	<b>— *** *** ***</b>	n.i. n.c.n	
Auto	□BCR/ABL p210 Quantitative PC		☐ FLT3 ITD by PCR		
Syngeneic	(for CML, Ph+ ALL and known p210)		□ NPM1 Mutation by PCR		
□ Non Transplant	□BCR/ABL p190 Quantitative PCR		□CEBPa Mutation by PCR		
Protocol #	(for Ph+ ALL and known p190)		□Other:		
Transplant Date://	Tabada bada ada ada ada ada ada ada ada a	1			
Donor Name/URD#:	Labs to be done at Seattle Children		ICT agazamara	ny any raquasts made for	
Danier Candon, F.M.; F.F.;	A separate CIS requisition MUST accompany any requests made for				
Donor Gender: ☐ Male ☐ Female	labs that will be run by SCH/UW Virology				